GTBP News and Press, GT Biopharma Inc. From 11/08/21

Gainers: Pioneer Power Solutions (NASDAQ:PPSI) +88%. CBAK Energy Technology (NASDAQ:CBAT) +39%. Arbe (NASDAQ:ARBE) +33%. The Trade Desk (NASDAQ:TTD) +29%. Autolus (NASDAQ:AUTL) +25%. Gaucho Group (NASDAQ:VINO) +24%. Cronos (NASDAQ:CRON) +21%. Bit Brother (NASDAQ:BTB) +22%. Lightbridge (NASDAQ...

Shares of GT Biopharma (GTBP -20.7%) are down significantly today after the company said CEO Anthony Cataldo and CFO Michael Handelman have left the company. The company's board has appointed Gregory Berk and Gavin Choy, respectively, as acting CEO and CFO. GT also appointed&#x...

Gainers: Autolus Therapeutics AUTL +33%, PetVivo PETV +21%, Cronos (NASDAQ:CRON) +19%, Tenaya Therapeutics (NASDAQ:TNYA) +16%, Privia Health PRVA +13%. Losers: GT Biopharma (NASDAQ:GTBP) -29%, Ontrak (NASDAQ:OTRK) -19%, Molecular Partners...

GT Biopharma Announces Executive Leadership Transition to Implement Next Phase of Strategic Journey - Appoints Dr. Gregory Berk, current President of R&D and Chief Medical Officer, as Interim Chief Executive Officer - Names Michael Breen, current Board member, as Executi...

GT BioPharma's Next Generation Camelid TriKE® Nanobody Platform Highlighted at ESMO Congress 2021 - Preclinical data presented at ESMO demonstrates activity of the camelid TriKE in B7H3 positive and HER2+ solid tumor cancer models - In addition, the company also provide...

GT Biopharma Announces Updated Positive Safety Data From Phase 1 GTB-3550 Monotherapy TriKE™ Trial an Investigational Immunotherapy for Refractory Cancers to be Presented at ESMO Congress 2021 - Abstract presented by Jeffrey Miller, MD, University of Minnesota Medical Sch...

GT Biopharma Advances GTB-3650, a Second-Generation Tri-Specific Killer Engager -TriKE®, Into IND-Enabling Studies - GTB-3650 is a novel molecule based on camelid single-domain antibody technology with advantages that build upon the strong proof-of-concept data from the Com...

GT Biopharma Announces Issuance of Two New Patents Covering TriKE® Platform Technologies - Intellectual property related to the TriKE® platform technology underpinning novel portfolio of molecules protected through 2036 PR Newswire BEVERLY HILLS, Calif. ...

GT Biopharma to Present at Upcoming September Investor Conferences - H.C. Wainwright 23rd Annual Global Healthcare Conference - Baird Global Healthcare Conference PR Newswire BEVERLY HILLS, Calif. , Sept. 8, 2021 /PRNewswire/ -- GT Biopharma, Inc. (N...

GT Biopharma Announces the Promotion of Dr. Gregory Berk to President of Research & Development and Chief Medical Officer GT Biopharma Announces the Promotion of Dr. Gregory Berk to President of Research & Development and Chief Medical Officer In his expanded role, D...